Next Article in Journal
Climate Change and Enteric Infections in the Canadian Arctic: Do We Know What’s on the Horizon?
Previous Article in Journal
Aspects of the Pathogenesis and Management of Inflammatory Bowel Diseases
Article

Cardiomyocyte-Specific Circulating Cell-Free Methylated DNA in Esophageal Cancer Patients Treated with Chemoradiation

Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Takuji Tanaka
Gastrointest. Disord. 2021, 3(3), 100-112; https://0-doi-org.brum.beds.ac.uk/10.3390/gidisord3030011
Received: 22 December 2020 / Revised: 28 July 2021 / Accepted: 29 July 2021 / Published: 30 July 2021
Thoracic high-dose radiation therapy (RT) for cancer has been associated with early and late cardiac toxicity. To assess altered rates of cardiomyocyte cell death due to RT we monitored changes in cardiomyocyte-specific, cell-free methylated DNA (cfDNA) shed into the circulation. Eleven patients with distal esophageal cancer treated with neoadjuvant chemoradiation to 50.4 Gy (RT) and concurrent carboplatin and paclitaxel were enrolled. Subjects underwent fasting blood draws prior to the initiation and after completion of RT as well as 4–6 months following RT. An island of six unmethylated CpGs in the FAM101A locus was used to identify cardiomyocyte-specific cfDNA in serum. After bisulfite treatment this specific cfDNA was quantified by amplicon sequencing at a depth of >35,000 reads/molecule. Cardiomyocyte-specific cfDNA was detectable before RT in the majority of patient samples and showed some distinct changes during the course of treatment and recovery. We propose that patient-specific cardiac damages in response to the treatment are indicated by these changes although co-morbidities may obscure treatment-specific events. View Full-Text
Keywords: esophageal cancer; therapy response; circulating cell-free DNA; DNA methylation; amplicon sequencing esophageal cancer; therapy response; circulating cell-free DNA; DNA methylation; amplicon sequencing
Show Figures

Figure 1

MDPI and ACS Style

Martinez Roth, S.; Vietsch, E.E.; Barefoot, M.E.; Schmidt, M.O.; Park, M.D.; Ramesh, A.; Lindberg, M.R.; Giaccone, G.; Riegel, A.T.; Barac, A.; Unger, K.; Wellstein, A. Cardiomyocyte-Specific Circulating Cell-Free Methylated DNA in Esophageal Cancer Patients Treated with Chemoradiation. Gastrointest. Disord. 2021, 3, 100-112. https://0-doi-org.brum.beds.ac.uk/10.3390/gidisord3030011

AMA Style

Martinez Roth S, Vietsch EE, Barefoot ME, Schmidt MO, Park MD, Ramesh A, Lindberg MR, Giaccone G, Riegel AT, Barac A, Unger K, Wellstein A. Cardiomyocyte-Specific Circulating Cell-Free Methylated DNA in Esophageal Cancer Patients Treated with Chemoradiation. Gastrointestinal Disorders. 2021; 3(3):100-112. https://0-doi-org.brum.beds.ac.uk/10.3390/gidisord3030011

Chicago/Turabian Style

Martinez Roth, Sarah, Eveline E. Vietsch, Megan E. Barefoot, Marcel O. Schmidt, Matthew D. Park, Archana Ramesh, Michael R. Lindberg, Giuseppe Giaccone, Anna T. Riegel, Ana Barac, Keith Unger, and Anton Wellstein. 2021. "Cardiomyocyte-Specific Circulating Cell-Free Methylated DNA in Esophageal Cancer Patients Treated with Chemoradiation" Gastrointestinal Disorders 3, no. 3: 100-112. https://0-doi-org.brum.beds.ac.uk/10.3390/gidisord3030011

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop